e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Viatris Inc. - Common Stock (NQ:VTRS)

14.34 -0.02 (-0.14%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Viatris Inc. - Common Stock

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

7 Pharmaceutical Stocks That Could Make You Rich ↗

January 06, 2022

Due to expiring patents and rising competition, successful pharmaceutical stocks need to develop robust drug pipelines. 7 Pharmaceutical Stocks That Could Make You Rich

Via InvestorPlace

7 of the Best Cheap Stocks Under $20 for 2022 to Buy Now ↗

January 03, 2022

These cheap stocks are trading at highly attractive prices and have the potential to break through this year.

Via InvestorPlace

10 Worst Performing S&P 500 Stocks Of 2021 ↗

December 31, 2021

The S&P 500 delivered one of its best years in recent history in 2021, gaining more than 27%. Most U.S. investors had a lot of winners in their portfolios this year, but some...

Via Benzinga

7 of the Best Value Stocks for 2022 to Buy Now ↗

December 15, 2021

Among the best value stocks, these seven provide both deep value and upside potential. Buy now for future gains in 2022.

Via InvestorPlace

Jim Cramer Shares His Warning On Nio, Expresses Support For TJX And More ↗

December 14, 2021

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he doesn’t like NIO Inc. (NYSE:

Via Benzinga

India's Biocon Mulls Merger Of Biosimilar Business With Mylan: Moneycontrol ↗

December 09, 2021

India-based Biocon Ltd is reportedly in talks with generic drugmaker Mylan for a merger of their biosimilar businesses, financial news website ...

Via Benzinga

The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment; Regulatory Setbacks For CTI Biopharma, BioXcel; Favorable Ruling For Viatris In Tecfidera Patent Case ↗

December 01, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Adcom Backing For Oral COVID-19 Antiviral Medication Molnupiravir...

Via Benzinga

Topics Intellectual Property

7 Drug Stocks to Buy Now While They’re Still on Sale ↗

November 30, 2021

Covid-19 stocks soared to unsustainable highs as investors ignored drug stocks with a deep pipeline of products for the decade ahead.

Via InvestorPlace

Topics Supply Chain

Biogen Loses Bid To Revive Tecfidera Drug Patent: Bloomberg ↗

November 30, 2021

Biogen Inc (NASDAQ: BIIB) lost its appeals court bid to revive a key patent on the blockbuster multiple sclerosis drug Tecfidera, reports Bloomberg. In a related ruling...

Via Benzinga

Topics Intellectual Property

Is It Too Late to Buy Viatris Stock? ↗

November 30, 2021

It's not too late if you're looking for dividend income.

Via The Motley Fool

7 Stocks 'On Sale' This Holiday Season ↗

November 26, 2021

This time of year, it may feel like you’ve missed out on big rallies in the best stocks. But, there may still be a chance to buy some high-quality stocks for 2022 at a discount to what you would have...

Via Talk Markets

7 Stocks 'On Sale' This Holiday Season ↗

November 26, 2021

The SPDR S&P 500 ETF Trust (NYSE: SPY) has generated a total return of 26.4% year-to-date, but much of those overall gains have been driven by a handful of megacap stocks. In...

Via Benzinga

Topics Stocks

3 Pharma Stocks That Are Too Cheap to Ignore ↗

November 25, 2021

Many stocks are ridiculously expensive right now -- but not these three.

Via The Motley Fool

Novartis May Have Buyer(s) For Its Sandoz Unit - Report ↗

November 23, 2021

According to a German newspaper, Swedish-based investment group EQT and the Struengmann family of Germany are considering a joint move to purchase the Novartis AG...

Via Benzinga

New Alternatives for Branded Biologics ↗

November 22, 2021

We’ve all heard about generic drugs. They are time-tested and battle-proven medicines that are more affordable than their patented predecessors. Branded drugs consistently...

Via Benzinga

7 Stocks to Buy for Their Resistance to the 6.2% Monthly Inflation ↗

November 22, 2021

These companies either have no exposure to inflation or have strong branding and customer loyalty, enabling them to pass higher costs.

Via InvestorPlace

3 Things About Viatris That Smart Investors Know ↗

November 21, 2021

Don't expect it to follow the trajectory of a hot growth stock.

Via The Motley Fool

Johnson & Johnson Pops As It Announces The Biggest Split In Health Care ↗

November 12, 2021

Johnson & Johnson will split its consumer health unit into a publicly traded company.

Via Investor's Business Daily

The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More ↗

November 08, 2021

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...

Via Benzinga

Could Viatris Stock Help You Retire a Millionaire? ↗

October 23, 2021

It depends on how much help you're looking for.

Via The Motley Fool

Topics Retirement

Earnings Scheduled For November 8, 2021 ↗

November 08, 2021

Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million. •...

Via Benzinga

3 No-Brainer Biotech Stocks to Buy Right Now ↗

October 16, 2021

Regeneron Pharmaceuticals, Vertex Pharmaceuticals, and Viatris should have plenty of room to run.

Via The Motley Fool

2 Ultra-Cheap Stocks Trading Below Their Book Values ↗

October 07, 2021

And these stocks also pay relatively high dividends.

Via The Motley Fool

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Viatris Inc. and Encourages Investors who Formerly Held Shares of Mylan Inc. (MYL) to Contact the Firm

September 29, 2021

From The Schall Law Firm

Via Business Wire

Why Are Theravance Bio Shares Plummeting Premarket Today? ↗

September 15, 2021

Theravance Biopharma Inc (NASDAQ: TBPH) will reduce its headcount by approximately 75% (estimated 270 positions), with most of the lay off to complete in November...

Via Benzinga

Why Wall Street Thinks This Dirt Cheap Value Stock Could Soar ↗

September 13, 2021

It's kind of a boring stock. But analysts think that it could deliver not-so-boring growth.

Via The Motley Fool

Got $5,000? These 2 Dividend Stocks Are Dirt Cheap Buys ↗

September 02, 2021

And their yields are both over 3%.

Via The Motley Fool

3 Things About Pfizer That Smart Investors Know ↗

August 31, 2021

They're all about the future.

Via The Motley Fool

Theravance Stock Crashes; Can Longer Testing Salvage Its J&J-Partnered Drug? ↗

August 24, 2021

Theravance said late Monday its ulcerative colitis treatment failed in midstage testing, and the biotech stock plummeted early Tuesday.

Via Investor's Business Daily

3 Top Biotech Stocks to Buy in August ↗

August 17, 2021

Each of these companies makes for a great vehicle to play an aging demographic.

Via The Motley Fool

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy